Video

Dr. Danila on how he chooses among androgen receptor inhibitors in castration-resistant prostate cancer

Daniel C. Danila, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses choosing among the androgen receptor inhibitors darolutamide (Nubeqa), enzalutamide (Xtandi), and apalutamide (Erleada) when treating patients with castration-resistant prostate cancer.

© 2025 MJH Life Sciences

All rights reserved.